Artwork

Content provided by Financial Times. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Financial Times or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Walmsley's GSK gamble

9:06
 
Share
 

Manage episode 223921512 series 8013
Content provided by Financial Times. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Financial Times or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

GlaxoSmithKline is combining its consumer health business with that of US rival Pfizer, paving the way for a separation of its core consumer and pharmaceuticals businesses within three years. Chief executive Emma Walmsley is betting the cash generated by the enlarged consumer unit will fund further investment in the pharmaceutical business ahead of the demerger. Matthew Vincent is joined by Sarah Neville and Arash Massoudi to discuss the merits of the deal and its implications for the health and pharmaceuticals markets.


Contributors: Naomi Rovnick, FT Live reporter, Matthew Vincent, Lombard columnist, Sarah Neville, global pharmaceuticals editor and Arash Massoudi, corporate finance and deals editor. Producer: Sam Westran



Hosted on Acast. See acast.com/privacy for more information.

  continue reading

1276 episodes

Artwork

Walmsley's GSK gamble

FT News in Focus

4,822 subscribers

published

iconShare
 
Manage episode 223921512 series 8013
Content provided by Financial Times. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Financial Times or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

GlaxoSmithKline is combining its consumer health business with that of US rival Pfizer, paving the way for a separation of its core consumer and pharmaceuticals businesses within three years. Chief executive Emma Walmsley is betting the cash generated by the enlarged consumer unit will fund further investment in the pharmaceutical business ahead of the demerger. Matthew Vincent is joined by Sarah Neville and Arash Massoudi to discuss the merits of the deal and its implications for the health and pharmaceuticals markets.


Contributors: Naomi Rovnick, FT Live reporter, Matthew Vincent, Lombard columnist, Sarah Neville, global pharmaceuticals editor and Arash Massoudi, corporate finance and deals editor. Producer: Sam Westran



Hosted on Acast. See acast.com/privacy for more information.

  continue reading

1276 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide